Pure Global
NCT06155682

TMS for Inhibition Enhancement in Schizophrenia

Cognitive and Neural Correlates of TMS Motor Intracortical Inhibition in Schizophrenia
University of Maryland, Baltimore·ClinicalTrials.gov·device·Device trialNot yet recruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Schizophrenia
Drug/Device/Intervention
repetitive transcranial magnetic stimulation
Study type
Interventional
Intervention type
device
Sponsor & location
Primary sponsor
University of Maryland, Baltimore
Timeline & enrollment
Phase
N/A
Start date
Mar 01, 2025
End date
Dec 01, 2028
Enrollment
34 participants
Primary outcome

The change in the short interval intracortical inhibition (SICI) score

Summary

This study purpose is to perform a pilot mechanistic trial repetitive transcranial magnetic
 stimulation (rTMS) clinical trial in 34 people with schizophrenia (Sz). The trial will
 evaluate whether inhibitory 1 Hertz (Hz) rTMS targeting motor cortex can increase brain
 inhibition reflected in a decrease in the short-interval intracortical inhibition (SICI)
 score from pre-to-post-treatment. We will also collect preliminary data on the effect of rTMS
 on the resting functional connectivity of the motor cortex and other brain regions and the
 relationship of change in SICI to change in cognitive performance

ICD-10 classifications
SchizophreniaSimple schizophreniaSchizophrenia, unspecifiedOther schizophreniaParanoid schizophrenia
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06155682
Type
Device Trial
About this record

Access comprehensive clinical trial information for NCT06155682 through Pure Global AI's free database. This phase not specified trial is sponsored by University of Maryland, Baltimore and is currently Not yet recruiting. The study focuses on Schizophrenia. Target enrollment is 34 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.